^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Published date:
04/27/2023
Excerpt:
Ampullary Adenocarcinoma….Poor PS:...Intestinal Type, For select patients with ECOG 2 consider multi-agent regimens:...5-FU + leucovorin ± bevacizumab.